⌘K
David Hallas (CEO) and Chris Wilks (CFO) of ECO Animal Health conducted a live presentation covering the company's Interim Results for the period to 30th September. Highlights included a 19% increase in Group Revenue, and Gross Margins rising to 49.6% (H1 2024: 40.3%), driven by improved pricing and lower input costs. Management highlighted the Positive Opinion received ahead of schedule from the European Medicines Agency for ECOVAXXIN® MS, the Group's poultry vaccine against Mycoplasma synoviae, establishing an anticipated EU commercial launch in H2 CY2026. The team provided a detailed financial review included an increase in adjusted EBITDA and cash balances, updated viewers on the R&D growth engine, and then answered a range of questions submitted by investors. Equity Development's latest research on ECO Animal Health Group plc (AIM: EAH) is freely accessible here: https://www.equitydevelopment.co.uk/research/fy26-interims-momentum-accelerates The full video has been divided into chapters, for ease of viewing, as below: Timestamps 0:00:00 Introduction & H1 summary 0:02:41 Financial highlights 0:06:55 ECO in short 0:10:48 Financial review 0:23:48 R&D growth engine 0:27:58 Summary & Outlook 0:31:07 Questions & Answers
